Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIANTU001 in dominantly inherited Alzheimer's disease
ISRCTN90795724Phase 3Completed
- Sponsor
- Washington University in St. Louis
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Gantenerumab arm with Solanezumab arm (2 arms). Primary endpoints: Safety and tolerability of gantenerumab and solanezumab, Adverse events and serious adverse events and 1 more. Started Jan 2014; status: completed.
02
Drugs
gantenerumabsolanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ISRCTN90795724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90795724.